E
EyePoint EYPT
$0.31
−4.23%
Nov 13
1W
1M
3M
6M
1Y
3Y
5Y
Key indicators
Sales
−94%
$2.58M over 12 months
Net margin
−10,995%
Low
High
Volatility
131%
Calm
Choppy
Bars: against the 40 close companies.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
Earnings release
The day the company publishes its quarterly accounts: revenue, profit, and often its outlook. The price sometimes moves sharply that day, in either direction. Over the long term, what matters is the trend of profits from one quarter to the next, not the reaction of the day.
Posts
No posts about EYPT yet.
About EyePoint, Inc. Common Stock
EyePoint is a clinical-stage biotech in Watertown, Massachusetts, developing sustained-release eye drugs. Its lead candidate, Duravyu, is an insert that slowly releases a drug inside the eye, now in Phase 3 trials for diabetic macular edema. It has almost no sales and pays its bills from cash raised from investors.